Registration

Opening speech

Biopharma 2020 - Emerging Biological Therapies Realizing the Promise of Biologics

Create strategic opportunities from globalization - a new paradigm of biopharma industry and supply chain

Towards Industry 4.0 – Create a digitalized biopharma environment

Break

"Next-generation" antibody manufacturing trends and case sharing

Considerations on commercial manufacturing of biosimilars

Luncheon

Innovation in biologics manufacturing: towards personalized drugs

Automation and digitalization help realize high-throughput development of new biologics from cloning to clinical application

Single-use technology enabled domestic biopharma industry by accelerating R&D and manufacturing

Break

Simplicity is the core advantage of quality control system

Industrialization of cell and gene therapy

Establish quality control system from laboratory to plant

Panel discussion: Biopharma manufacturing in the era of digitalization

Status of biopharma industry: which new trend will grow the fastest?
Adopt modular automation, PAT and continuous processing to increase flexibility and efficiency
Person and technology: how do these forces work together to promote the industry?
IoT- How do cloud-based data, data analytics, and data integrity continuously help improve compliance and quality?

p>

End of Day 1

Registration

Standard and guidance agreement for disposable products and single use systems

Challenges of single-use facilities in biopharmaceutical flexible manufacturing

Real-time monitoring and advances in high-throughput analysis of biopharmaceutical manufacturing

Break

Continuous upstream process design - challenges and solutions

Strategy for expressing protein targets that are difficult to express

Glycosylation throughput analysis in mAb CHO cell culture

Luncheon

Saving process development time with next-generation methods: PAT, hybrid modeling, process simulation, mDoe and iDoE

Continuous downstream processing: comparability and regulatory risk

Optimization in the later process development and end-to-end continuous cell culture and manufacturing

Break

How to achieve quality control and continuous verification across the biopharmaʼs life cycle

Develop downstream development process with high-throughput process development platform

Enhancing Virus Filter Throughput for Hydrophobic Proteins

Purified plasmid DNA enables gene therapy

Panel discussion: As modern manufacturing systems based on single -use technology are getting more and more attention, how to design plants that meet the needs of the process?

End of Day 2

Registration

Revolution and development of cancer cell immunotherapy in future

Biomarker of non-small cell lung cancer (NSCLC) PD1/PDL1 McAb drives immunity therapy towards the era of precision medicine

Biosimilar development opportunities and challenges

Break

Integration strategy for CLD cell line development for new drug clinical trials

Biopharmaceutical enterprisesʼ own platform development / cooperation model with outsourcing enterprises

Strategy for IND Declaration of Cell Therapy

Luncheon

Development and optimization of preclinical process for tumor immune BSAB

Sponsor

Design a combination regimen with different antibodies for tumor immunothe

Break

Discovery of antibodies for cancer treatment and important innovations in early development

Discovery of monoclonal antibody target and considerations on screening platform selection and optimization

Application of block-chain technology in clinical practice

Panel discussion: Feasibility Study and Action Plan on proposed Patent Linkage System for Pharmaceutical Products in China

End of Day 2